Biodexa Pharmaceuticals (BDRX)
NASDAQ:BDRX
BDRX Stock Chart & Stats
$2.33
$0.02(0.46%)
At close: 4:00 PM EST
$2.33
$0.02(0.46%)
Day’s Range― - ―
52-Week Range$2.86 - $96.50
Previous CloseN/A
Volume6.04K
Average Volume (3M)260.97K
Market Cap
$1.40M
Enterprise Value-$8.06M
Total Cash (Recent Filing)$8.52M
Total Debt (Recent Filing)$60.89K
Price to Earnings (P/E)―
Beta1.75
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding648,314
10 Day Avg. Volume685,915
30 Day Avg. Volume260,967
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.09
Enterprise Value/Market Cap-5.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.70
Enterprise Value/Ebitda0.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetA very low debt load and meaningful equity growth provide financial flexibility for a clinical-stage firm. This reduces near-term solvency risk, lowers interest burden, and gives management optionality to fund trials or pursue partnerships without immediate debt constraints, supporting multi-quarter development plans.
Focused GI/oncology Pipeline With Registrational AssetShifting to a concentrated GI/oncology strategy anchored by a Phase 3 registrational eRapa trial materially clarifies the development path. A registrational program can shorten time to a commercialization decision or partnering, concentrating R&D resources and improving the probability of a durable clinical or strategic outcome.
In-licensed MTX240 With Patent ProtectionThe Otsuka license adds a mechanistically differentiated, Phase 1‑ready asset addressing TKI-resistant GIST and brings composition‑of‑matter patent protection through 2037. This strengthens program diversification, extends potential commercial exclusivity, and enhances partnering and out‑licensing optionality over the medium term.
Bears Say
Zero Revenue And Persistent LossesAbsent product revenue, the company lacks internal earnings to fund operations; persistent operating losses mean ongoing reliance on capital markets or partners. If development timelines slip, prolonged losses could erode equity and limit strategic choices, making the business model dependent on external funding.
Ongoing Negative Cash Flow And BurnAlthough operating outflows narrowed, free cash flow remains negative and volatile. Continued cash burn creates predictable funding needs over successive quarters, increasing the probability of dilutive financings or urgent partnering, which can materially affect long‑term shareholder value and program continuity.
Listing Compliance Action Reflects Market PressureA reverse ADR split to meet listing thresholds signals sustained low market prices and investor confidence issues. This structural capital-market pressure can shrink the investor base, complicate future equity raises, and impose governance or disclosure burdens that persistently constrain strategic flexibility.
Biodexa Pharmaceuticals News
BDRX FAQ
What was Biodexa Pharmaceuticals’s price range in the past 12 months?
Biodexa Pharmaceuticals lowest stock price was $2.86 and its highest was $96.50 in the past 12 months.
What is Biodexa Pharmaceuticals’s market cap?
Biodexa Pharmaceuticals’s market cap is $1.40M.
When is Biodexa Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Biodexa Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Biodexa Pharmaceuticals overvalued?
According to Wall Street analysts Biodexa Pharmaceuticals’s price is currently Overvalued.
Does Biodexa Pharmaceuticals pay dividends?
Biodexa Pharmaceuticals does not currently pay dividends.
What is Biodexa Pharmaceuticals’s EPS estimate?
Biodexa Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biodexa Pharmaceuticals have?
Biodexa Pharmaceuticals has 648,314 shares outstanding.
What happened to Biodexa Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biodexa Pharmaceuticals?
Currently, no hedge funds are holding shares in BDRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Technical Analysis
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
Enveric Biosciences
―
CNS Pharmaceuticals
―
Ownership Overview
―
Insiders
34.66% Other Institutional Investors
65.34% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---